Melanoma peptide vaccines: From preclinical background to clinical trials

Current Oncology Reports

Volumn 2, Issue 1, 2000, Pages 38-47

  Weber, Jeffrey ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Gp100 Peptide; Melanoma; Melanoma Patient; Metastatic Melanoma; Peptide Vaccine

Indexed keywords

CANCER VACCINE; SUBUNIT VACCINE; TUMOR ANTIGEN;

CLINICAL TRIAL; HUMAN; IMMUNOLOGY; MELANOMA; REVIEW; SKIN TUMOR; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS; HUMANS; MELANOMA; SKIN NEOPLASMS; T-LYMPHOCYTES; VACCINES, SUBUNIT;

EID: 0033732704     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-000-0009-9     Document Type: Article

References (94)

1. Townsend ARM, Gotch RM, Davey J: Cytotoxic cells recognize fragments of the influenza nucleoprotein. Cell 1985, 42:457–467.
2. Townsend ARM, Rothbard J, Gotch FM, et al.: The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986, 44:959–968.
3. Maryanski JL, Paola P, Coradin G, et al.: H-2 restricted cytotoxic T cells specific for HLA can recognize a synthetic HLA peptide. Nature 1986, 324:578–579.
4. Clark WH, Elder DE, Guerry DE, et al.: A model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989, 81:1893–1898.
5. Paladugu RR, Yonemoto RH: Biologic behavior of thin melanomas with regressive changes. Arch Surg 1983, 118:41–45.
6. Bystryn JC, Rigel D, Friedman RJ, Kopf A: Prognostic signficance of hypopigmentation in malignant melanoma. Arch Dermatol 1987, 123:1053–1055.
7. Richards JM, Mehta M, Schroeder, et al.: Sequential chemoimmunotherapy for metastatic melanoma. J Clin Oncol 1992, 9:1152–1160.
8. Nordlund JJ, Kirkwood JM, Forget BM, et al.: Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Derm 1983, 9:689–697.
9. Anichini A, Mazzocchi A, Fossatti G, Parmiani G: Cytotoxic T lymphocyte clones from peripheral blood and from tumor sites detect intra-tumoral heterogeneity of melanoma cells: analysis of specificity and mechanisms of interaction. J Immunol 1989, 142:3692–3701.
10. Wolfel T, Klehmann E, Muller C, et al.: Lysis of human melanoma cells by autologous cytolyitc T cell clones: identification of human histocompatibility leucocyte antigen A2 as a restriction element for three different antigens. J Exp Med 1989, 170:797–805.
11. Topalian SL, Solomon D, Rosenberg SA: Tumor specific cytolysis by lymphocytes infiltrating human tumors. J Immunol 1989, 142:3714–3725.
12. Van DerBruggenP, Traversari C, Chomez P, et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643–1647. The very first report of the cloning of a human gene encoding a tumor antigen recognized by T-cells: MAGE-1.
13. Traversari C, van der Bruggen P, Luescher I, et al.: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992, 176:1453–1457.
14. Gauler B, van denEyndeB, van derBruggenP, et al.: Human gene MAGE-3 codes for an antigen recognized on melanoma cells by autologous lymphocytes. J Exp Med 1994, 179:921–929.
15. Kawakami Y, Eliyahu S, Delgado C, et al.: Cloning of the gene coding for a shared melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 1994, 96:3515–3519.
16. Coulie PG, Brichard V, Van PelA, et al.: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994, 180:35–42.
17. Kawakami Y, Eliyahu S, Sakaguchi K, et al.: Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994, 180:347–352.
18. Stevens E, Jacknin L, Robbins PF, et al.: The generation of tumor specific cytotoxic lymphocytes from melanoma patients using peripheral blood stimulated with allogeneic melanoma tumor cell lines: fine specificity and MART-1 melanoma antigen recognition. J Immunol 1995, 154:762–0767.
19. Romero P, Gervois N, Schneider J, et al.: Cytolytic T lymphocyte recognition of the immunodominant HLA-A *0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J Immunol 1997, 159:2366–2374.
20. Rivoltini L, Kawakami Y, Sakaguchi K, et al.: Induction of tumor reactive CTL from peripheral blood and tumorinfiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995, 154:2257–2265.
21. Cole DJ, Weil DP, Shilyansky J, et al.: Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1melanoma tumor antigen. Cancer Res 1995, 55:748–752.
22. Sensi M, Salvi S, Castelli C, et al.: T cell receptor structure of autologous melanoma reactive cytotoxic T lymphocyte (CTL) clones: tumor infiltrating lymphocytes overexpress in vivo the TCR chain sequence used by an HLA-A2 restricted and melanocyte lineage-specific CTL clone. J Exp. Med 1993, 178:1231–1248.
23. Hunt DF, Henderson RA, Shabanowitz J, et al.: Chracterization of peptides bound to the class I molecule HLA-A2.1 by mass spectrometry. Science 1992, 255:1261–1264.
24. Storkus WJ, Zeh HJ, Maeurer MJ, et al.: Identification of human melanoma peptides recognized by class I restricted tumor infiltrating lymphocytes. J Immunol 1993, 151:3719–3726.
25. Cox AL, Skipper J, Chen Y, et al.: Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994, 264:716–719.
26. Loftus DJ, Castelli C, Clay TM, et al.: Identification of epitope mimics recognized by CTL reactive to the melanoma/ melanocyte-derived peptide MART-1(27-35). J Exp Med 1996, 184:647–657.
27. Marincola FM, Rivoltini L, Salgaller ML, et al.: Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. J Immunother 1996, 19:266–277.
28. Romero P, Dunbar PR, Valmori D, et al.: Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigenexperienced tumor specific cytolytic T lymphocytes. J Exp Med 1998, 188:1641–1650. The first report of the presence of tumor-specific memory T-cells in lymph nodes draining tumors in patients with melanoma.
29. Fleischhauer K, Tanzarella S, Wallny HJ, et al.: Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line. J Immunol 1996, 157:787–797.
30. Rivoltini L, Loftus DJ, Barracchini K, et al.: Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. J Immunol 1996, 156:3882–3891.
31. Schneider J, Brichard V, Boon T, et al.: Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1. J Natl Inst Cancer 1998, 75:451–458.
32. MarincolaFM: Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy. J Immunol 1998, 161:877–889.
33. Jimenez M, Maloy WL, Hearing VJ: Specific identification of an authentic clone for mammalian tyrosinase. 1989 J Biol. Chem 1989. 264:3397–3403.
34. Adema GJ, DeBoer AJ, Vogel AM, et al.: Molecular characterization of the melanocyte lineage specific antigen gp100. J Biol Chem 1994, 269:20126–20133.
35. Bakker ABH, Schreurs WJ, de BoerAJ, et al.: Melanocyte lineage specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994, 179:1005–1011. This report describes a new human melanoma tumor antigen recognized by T-cells—gp100—which is the glycoprotein recognized by the HMB-45 antibody.
36. Kawakami Y, Eliyahu S, Delgado C, et al.: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A 1994, 91:6458–6462.
37. Bakker ABH, Schreurs MWJ, et al.: Identification of a novel peptide derived from the melanocyte specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1 restricted anti-melanoma CTL line. Int J Cancer 1995, 62:97–102.
38. Skipper JC, Kittlesen DJ, Hendrickson RC, et al.: Shared epitopes for HLA-A3 restricted melanoma-reactive human cytolytic T lymphocytes include a naturally processed epitope from pMel17/gp100. J Immunol 1996, 157:5027–5033.
39. Kawashima I, Tsai V, Southwood S, et al.: Idenitification of gp100-derived melanoma-specific cytolytic T lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells. Int J Cancer 1998, 78:518–524.
40. Brichard V, Van Pel A, Wolfel T, et al.: The tyrosinase gene encodes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993, 178:489–495.
41. Wolfel T, Van Pel A, Brichard V, et al.: Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994, 24:759–764.
42. Skipper JCA, Hendrickson RC, Gulden PH, et al.: An HLA-A2 restricted tyrosinase antigen on melanoma cells results from post-translational modification and suggests a novel processing pathway for membrane proteins. J Exp Med 1996, 183:527–534.
43. Wang RF, Robbins PF, Kawakami Y, et al.: Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31 restricted tumor-infiltrating lymphocytes. J Exp Med 1995, 181:799–806.
44. Wang R-F, Parkhurst MR, Kawakami Y, et al.: Utilization of an alternative open reading frame of a normal gene in generating a human cancer antigen. J Exp Med 1996, 183:1131–1138.
45. Wang R-F, Appella E, Kawakami Y, et al.: Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996, 184:2207–2214.
46. Jaeger E, Chen Y-T, Drijfhout JW, et al.: Simultaneous humoral and cellular immune response against cancer testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2 binding peptide epitopes. J Exp Med 1998, 187:265–274. This report describes the cloning and definition of a new cancer testis antigen that is present on many tumors and melanomas and that can elicit T-cell and antibody responses.
47. Wang R-F, Johnston SL, Zeng G, et al.: A breast and melanomashared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. 1998 J Immunol 1998, 161:3596–3606.
48. Wolfel T, Hauer M, Schneider J, Serrano M, et al.: A p16INK4ainsensitive CDK4 mutant targeted by cytotoxic T lymphocytes in a human melanoma. Science 1995, 269:1281–1285.
49. Robbins PF, El-Gamil M, Li YF, et al.: A mutated b-catenin gene encodes a melanoma specific antigen recognized by tumorinfiltrating lymphocytes. J Exp Med 1996, 183:1185–1192.
50. Coulie PG, Lehmann F, Lethe B, et al.: A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A 1995, 92:7976–7980.
51. Marchand M, Weynants P, Rankin E, et al.: Tumor regression responses in melanoma patients treated with a peptide encoded by MAGE-3. Int J Cancer 1995, 63:883–885. The first report of clinical benefit in patients treated with a peptide vaccine. Surprisingly, no detectable T-cell responses were observed in responding patients.
52. Weber JS, Hua FL, Spears L, et al.: A Phase I trial of a HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund’s adjuvant in patients with resected high-risk melanoma. J Immunother 1999, in press.
53. Jaeger E, Bernhard H, Romero P, et al.: Generation of cytotoxic T cell responses with synthetic melanoma-associated peptide in vivo: implications for tumor vaccines with melanomaassociated antigens. Int J Cancer 1996, 66:162–170.
54. Jaeger E, Ringhoffer M, Dienes H-P, et al.: Granulocyte macrophage colony stimulating factor enhances immune responses to melanoma associated peptides in vivo. Int J Cancer 1997, 67:54–62.
55. Marchand M, van Baren N, Weynants P, et al.: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999, 80:219–230.
56. Cebon JS, Jaeger E, Gibbs P, et al.: Phase I studies of immunization with Melan-A and IL-12 in HLA-A2 positive patients with stage III and IV metastatic melanoma [abstract]. Proc ASCO 1999, 18:434A.
57. Scheibenbogen C, Schmittel A, Keiholz U, et al.: Vaccination with tyrosinase peptides and GM-CSF in metastatic melanoma Proc ASCO 1999, 18:436A.
58. Salgaller MM, Marincola FM, et al.: Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996, 56:4749–4757.
59. Salgaller ML, Afshar A, Marincola FM, et al.: Recognition of multiple epitopes of the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995, 55:4972–4977.
60. Cormier JN, Salgaller ML, Prevette T, et al.: Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. 1997 Cancer J Sci Am 1997, 3:37–44.
61. Parkhurst MR, Salgaller ML, Southwood S, et al.: Improved induction of melanoma reactive CTL with peptides from melanoma antigen gp100 modified at HLA-A0201 binding residues. J Immunology 1996, 157:2536–2548.
62. Wang F, Bade E, Kuniyoshi C, et al.: Phase I trial of a MART-1 peptide vaccine with incomplete Freund’s adjuvant for resected high-risk melanoma. Clin Cancer Res 1999, in press.
63. Valmori D, Fonteneau JF, Lizana CM, et al.: Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998, 160:1750–1758.
64. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 1998, 4:321–327. Report of an extensive series of pilot trials in which patients with metastatic melanoma were immunized with different melanoma peptides with an adjuvant and had detectable immune responses especially when a substituted gp100 peptide was used in the vaccine. When high-dose interleukin 2 (IL-2) was added to the gp100 melanoma vaccine regimen, significantly increased antitumor responses were observed compared with IL-2 alone.
65. Rosenberg SA, Lotze MT, Yang JC, et al.: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1990, 210:474–480.
66. Parkinson DR, Abrams JS, Wiernik PH, et al.: Interleukin-2 therapy in patients with metastatic melanoma: a phase II study. J Clin Oncol 1990, 8:1650–1659.
67. Lewis JJ, Janetski S, Wang S, Williams S, et al.: Phase I trial of vaccination with tyrosinase peptide plus QS-21 in melanoma. Proc ASCO 1998, 17:1650A.
68. Mukherji B, Chakraborty NG, Yamasaki S, et al.: Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995, 92:8079–8082.
69. Gajewski TF, Fallarino F, Vogelzang N, et al.: Effective antigenspecific vaccination without dendritic cells (DC): a phase I study of immunization with MAGE-3 or Melan-A peptidepulsed autologous PBMC plus rhuIL-12. Proc ASCO 1999, 18:539A.
70. Rosenberg SA, Zhou Y, Yang JC, et al.: Immunizing patients with metastatic melanoma using a recombinant adenovirus encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998, 90:1894–1900.
71. SteinmanRM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991, 9:271–290.
72. Van VoorhisWC, Hair SL, Steinman RM, et al.: Human dendritic cells:enrichment and characterization from human blood. J Exp Med 1982, 155:1172–1183.
73. Steinman RM, Witmer MD: Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte response in mice. Proc Natl Acad Sci U S A 1978, 75:5132–5136.
74. Inaba K, Metlay JP, Crowley MT, et al.: Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med 1990, 172:631–640.
75. Inaba K, Young JW, Steinman RM: Direct activation of CD8+ cytolytic T lymphocytes by dendritic cells. J Exp Med 1987, 166:182–194.
76. Macatonia SE, Taylor PM, Knight SC, et al.: Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T responses in vitro. J Exp Med 1988, 169:1255–1264.
77. Sallustro F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor. J Exp Med 1994, 179:1109–111822.
78. Romani N, Gruner S, Brang D, et al.: Proliferating dendritic cell progenitors in human blood. J Exp Med 1994, 180:83–93.
79. Van ElsasA, Van derBurgSH, Van DerMinneCE, et al.: Peptidepulsed dendritic cells induce tumoricidal cytolytic T cells from healthy donors against stable HLA-A0201 binding peptides from Melan A/MART-1 self antigen. Eur J Immunol 1996, 26:1683–1689.
80. Nestle FO, Alijagic S, Gilliet M, et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med 1998, 4:378–332. The first report of clinical and immune responses in patients treated with dendritic cells derived from human peripheral blood and grown ex vivo with interleukin-4 and granulocyte-macrophage colonystimulating factor.
81. Chen YT, Stockert E, Jungbluth A, et al.: Serological analysis of Melan-A (MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci U S A 1996, 93:5915–5919.
82. Marincola FM, Hijazi YM, Fetsch P, et al.: Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother 1996, 19:192–205.
83. Kageshita T, Kawakami Y, Hirai S, Ono T: Differential expression of MART-1 in primary and metastatic melanoma lesions. J Immunother 1997, 20:460–465.
84. Fetsch PA, Cormier J, Hijazi YM: Immunocytochemical detection of MART-1 in fresh and paraffin-embedded malignant melanomas. J Immunother 1997, 20:60–64.
85. de VriesTJ, Fourkour A, Wobbes T, et al.:.Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res 1997, 57:3223–3229.
86. Dalerba P, Ricci A, Russo V, et al.: High homogeneity of MAGE, BAGE, GAGE, tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: implications for protocol design of therapeutic antigen-specific vaccination strategies. Int J Cancer 1998, 77:200–204.
87. Cormier JN, Abati A, Fetsch P, et al.: Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J Immunother 1998, 21:27–31.
88. Maeurer MJ, Gollin SM, Martin D, et al.: Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 1996, 98:1633–1641.
89. Jaeger E, Ringhoofer M, Karbac J, et al.: Inverse relationship of melanoma differentiation antigen expression in melanoma tissues and CD8+ cytotoxic T cell responses: evidence for immunoselection of antigen loss variants in vivo. Int J Cancer 1996, 66:470–476.
90. Pittet MJ, Valmori D, Dunbar PR, et al.: High frequencies of naïve Melan A/MART-1-specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999, 190:705–715.
91. Lee PP, Yee C, Savage PA, et al.: Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature Med 1999, 5:677–685. The first report of the use of tetramer technology to detect and analyze circulating antigen-specific T-cells in melanoma patients in which significant defects in antigen-driven signal transduction were described.
92. Finke JH, Zea AH, Stanley J, et al.: Loss of T-cell receptor chain and p56lck in T-cells infiltrating human carcinomas. 1993 Cancer Res 1993, 53:5613–5618.
93. Nakagomi H, Petersson M, Magnusson I, et al.: Decreased expression of the signal-transducing chains in tumor infiltrating cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993, 53:5610–5612.
94. Zea AH, Brendan CD, Longo DL, et al.: Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995, 1:1327–1335.